🔗 Share this article

Given that America continues making sweeping adjustments to its vaccination schedules, a particular individual has surfaced unexpectedly: Høeg, a Danish American physician and epidemiologist who first made her name by expressing skepticism about COVID-19 shots in the global health crisis and has focused upon alleged fatalities after Covid vaccination in her brief time at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Schedule

Health officials had intended to announce sweeping revisions to the pediatric immunization program in December, aligning the US with the Danish vaccine program, according to reports – a major change that would put the US at odds with a large portion of the global community with insufficient data for benefit. The planned update has been pushed back until the next year.

Instead of the top vaccines chief, Dr. Høeg is set to speak at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this year.

Consolidating Power at the Agency

The acting appointment might represent a closer partnership between the drug and vaccine divisions as Dr. Høeg and Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for ending some pediatric shot schedules in the US to become more in line with Denmark's approach, a country with comprehensive healthcare and a citizenry about the size of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on vaccines – usually the responsibility of Dr. Prasad, director of the FDA’s vaccine center – instead of medication approval.

Questions Over Background

Høeg has no obvious background in drug development, approval processes or management, which has been customary for past leaders of the CBER. She has served at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in leading a large organization. She is not an expert in pharmaceutical oversight.”

Past directors of the center would “grasp legal statutes and the research of medication creation”, noted Dr. Janet Woodcock. “Clearly, she has not acquired the type of experience that prior appointees who headed the center have had.”

The drug center has an enormous workload at the agency, Woodcock pointed out.

“Everybody just zeroes in on the new drug program, but the generic drug division authorizes a multitude of generic drugs. There is also a biosimilars division, non-prescription drug unit and more, and each of these need to be managed,” Woodcock said. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a substantial leadership component to the job, which manages over 5,000 employees. “It is a huge leadership role, if you do it right,” Woodcock added.

Agency Reaction and Disputed Initiatives

In response to concerns about Høeg’s fitness for the role and whether this appointment represents increased cooperation among FDA leaders on vaccines, a spokesperson said that the “inquiries stem from inaccurate presumptions”.

“Her resume matches the duties of her position,” the representative explained, noting the period Dr. Høeg spent advising the FDA commissioner on “drug safety and oversight research, including computational safety modeling and immunization monitoring”.

As acting director, Høeg inherits the agency head's new fast-track approval initiative, a disputed one-day medication authorization process that apparently concerned her preceding directors. “By what process are these therapies being chosen for this fast-track system? Who makes the decisions?” Dr. Howard said. “There is a lot of confidentiality happening at the FDA right now.”

Overall, he stated, “the agency seems to be moving towards less stringent rules of all drugs, aside from shots.”

Public Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a more established, if troubling, history, Howard said. She released a research paper using non-validated volunteer-provided data to determine the rate of myocarditis after Covid immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccines are riskier than they are.

Part of her “wish list” for the new federal leadership included altering regulations for new vaccines and ending “unnecessary” immunizations, she stated after the election on a audio program. At the agency, Høeg has allegedly proposed barring adolescent males from receiving COVID-19 vaccinations.

“She’s an complete ideologue who starts off with her beliefs and tailors the evidence to accommodate the evidence in a very deceptive, dishonest way,” Dr. Howard stated.

Gaining Influence and a “Push for Payback”

Høeg joined fellow dissenters, {like|